In a recent series of podcasts conducted by UroToday, ImmunityBio, Inc. reveals groundbreaking developments in the field of bladder cancer research and the FDA approval of their novel therapy, ANKTIVA, for the treatment of non-muscle invasive bladder cancer (NMIBC).
ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guerin (BCG) has shown promising results in patients with carcinoma in situ (CIS), a type of NMIBC. The approval marks a significant advancement in therapeutic options for this aggressive form of bladder cancer.
Dr. Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific Officer at ImmunityBio, sheds light on the breakthrough and emphasizes the importance of exploring innovative treatment strategies. Dr. Ashish Kamat also joins the discussion, providing valuable insights into the potential implications of this treatment approach.
One key development that ImmunityBio highlights in the podcasts is their exclusive global arrangement with the Serum Institute of India, the largest vaccine manufacturer in the world. This agreement ensures the supply of Bacillus Calmette-Guerin (BCG) to ImmunityBio, allowing for expanded access to this crucial treatment option across various cancer types.
The collaboration encompasses the manufacturing of standard BCG (sBCG), which is approved for use outside the United States. Additionally, a next-generation recombinant BCG (iBCG) is currently undergoing testing and holds promise for its use in combination therapies.
Dr. Patrick Soon-Shiong’s expertise and insights will be further discussed at the Annual Conference of the American Urological Association. The approval of ANKTIVA and its implications for the treatment of NMIBC with CIS will be the focus of a fireside chat at this prestigious event.
ANKTIVA’s approval represents a significant step forward in the treatment of non-muscle invasive bladder cancer. Alongside ImmunityBio’s partnership with the Serum Institute of India, this breakthrough promises to improve outcomes for patients battling this challenging disease. The information shared in the UroToday podcasts and the upcoming discussion at the American Urological Association conference will further facilitate the understanding and implementation of this groundbreaking therapy.
Comments